leadf
logo-loader
viewIXICO PLC

IXICO plc - Conference attendance - On Helix Digital

RNS Number : 3203S
IXICO plc
08 July 2020
 

IXICO plc

("IXICO" or the "Company")

 

Conference attendance

On Helix Digital 13-14 July 2020

 

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces the Company's digital attendance at the On Helix Digital conference, on the 13-14 July 2020.

 

On Helix is a conference organised by One Nucleus, a non-for-profit Life Sciences & Healthcare organisation supporting institutions, companies and individuals working in the sector and connecting them. The event intends to bring organisations and investors together to share insights and innovation to support R&D companies in their current and future therapeutics and technology developments.

 

IXICO will share a pre-recorded presentation by Robin Wolz, SVP Science & Innovation at IXICO plc, titled 'Biomarkers for CNS clinical trials from imaging and actigraphy.' Two AI approaches to measure biomarkers in CNS disorders will be presented; the first approach is a method based on deep learning to segment brain volume in Huntington's disease and the second novel approach is the sleep assessment in Parkinson's disease from wrist-worn actigraphy. There will be an opportunity to set up one-to-one tele-meetings with potential customers and investors.

 

To find out and more and to register please visit: http://www.onhelix.com/

 

The pre-recorded presentation will also be made available on the Company's website shortly after the event:

https://ixico.com/investors/company-information/investor-videos/

 

For further information please contact:

 

IXICO plc

+44 (0)20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

 


 

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

 

Paul McManus / Lianne Cawthorne /

Mob: 07980 541 893 / 07584 391 303 /

Alice Woodings

07407 804 654

 

 

About IXICO (www.IXICO.com)

 

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

 

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAEAEXXEALEEAA

Quick facts: IXICO PLC

Price: 81.84

Market: AIM
Market Cap: £38.54 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO CEO 'delighted' with stronger than anticipated second half growth

IXICO PLC's (LON:IXI) Giulio Cerroni caught up with Proactive London's Katie Pilbeam after announcing they've raised earnings expectations for the current fiscal year. He says revenues for the year to the end of September 2020 will be in line with, or slightly ahead of, current market...

on 24/8/20